ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial
The Lancet Oncology
◽
10.1016/s1470-2045(18)30896-9
◽
2019
◽
Vol 20
(4)
◽
pp. 494-503
◽
Cited By ~ 110
Author(s):
David Ball
◽
G Tao Mai
◽
Shalini Vinod
◽
Scott Babington
◽
Jeremy Ruben
◽
...
Keyword(s):
Lung Cancer
◽
Randomised Controlled Trial
◽
Controlled Trial
◽
Small Cell
◽
Stereotactic Ablative Radiotherapy
◽
Small Cell Lung
◽
Open Label
◽
Phase 3
◽
Randomised Controlled
◽
Stage 1
Download Full-text
Related Documents
Cited By
References
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
The Lancet
◽
10.1016/s0140-6736(16)32517-x
◽
2017
◽
Vol 389
(10066)
◽
pp. 255-265
◽
Cited By ~ 1731
Author(s):
Achim Rittmeyer
◽
Fabrice Barlesi
◽
Daniel Waterkamp
◽
Keunchil Park
◽
Fortunato Ciardiello
◽
...
Keyword(s):
Lung Cancer
◽
Randomised Controlled Trial
◽
Small Cell Lung Cancer
◽
Controlled Trial
◽
Small Cell
◽
Small Cell Lung
◽
Open Label
◽
Phase 3
◽
Previously Treated
◽
Randomised Controlled
Download Full-text
Faculty Opinions recommendation of Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.726215272.793539632
◽
2017
◽
Author(s):
Patrick Nana-Sinkam
Keyword(s):
Lung Cancer
◽
Randomised Controlled Trial
◽
Controlled Trial
◽
Small Cell
◽
Phase 2
◽
Small Cell Lung
◽
Open Label
◽
Open Label Phase
◽
Previously Treated
◽
Randomised Controlled
Download Full-text
Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial
The Lancet Oncology
◽
10.1016/s1470-2045(20)30013-9
◽
2020
◽
Vol 21
(4)
◽
pp. 581-592
◽
Cited By ~ 14
Author(s):
Ursula Nestle
◽
Tanja Schimek-Jasch
◽
Stephanie Kremp
◽
Andrea Schaefer-Schuler
◽
Michael Mix
◽
...
Keyword(s):
Lung Cancer
◽
Randomised Controlled Trial
◽
Small Cell Lung Cancer
◽
Controlled Trial
◽
Locally Advanced
◽
Target Volume
◽
Small Cell
◽
Small Cell Lung
◽
Open Label
◽
Randomised Controlled
Download Full-text
Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial
The Lancet
◽
10.1016/s0140-6736(14)61085-0
◽
2015
◽
Vol 385
(9962)
◽
pp. 36-42
◽
Cited By ~ 229
Author(s):
Ben J Slotman
◽
Harm van Tinteren
◽
John O Praag
◽
Joost L Knegjens
◽
Sherif Y El Sharouni
◽
...
Keyword(s):
Lung Cancer
◽
Randomised Controlled Trial
◽
Small Cell Lung Cancer
◽
Controlled Trial
◽
Small Cell
◽
Thoracic Radiotherapy
◽
Small Cell Lung
◽
Phase 3
◽
Extensive Stage
◽
Randomised Controlled
Download Full-text
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
The Lancet Oncology
◽
10.1016/s1470-2045(12)70063-3
◽
2012
◽
Vol 13
(3)
◽
pp. 247-255
◽
Cited By ~ 370
Author(s):
Luis Paz-Ares
◽
Filippo de Marinis
◽
Mircea Dediu
◽
Michael Thomas
◽
Jean-Louis Pujol
◽
...
Keyword(s):
Lung Cancer
◽
Randomised Controlled Trial
◽
Supportive Care
◽
Controlled Trial
◽
Best Supportive Care
◽
Small Cell
◽
Small Cell Lung
◽
Phase 3
◽
Double Blind
◽
Randomised Controlled
Download Full-text
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
The Lancet
◽
10.1016/s0140-6736(21)00228-2
◽
2021
◽
Vol 397
(10274)
◽
pp. 592-604
◽
Cited By ~ 3
Author(s):
Ahmet Sezer
◽
Saadettin Kilickap
◽
Mahmut Gümüş
◽
Igor Bondarenko
◽
Mustafa Özgüroğlu
◽
...
Keyword(s):
Lung Cancer
◽
Controlled Trial
◽
Small Cell
◽
Line Treatment
◽
Small Cell Lung
◽
First Line
◽
Open Label
◽
Phase 3
◽
Randomised Controlled
◽
First Line Treatment
Download Full-text
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
The Lancet Oncology
◽
10.1016/s1470-2045(13)70586-2
◽
2014
◽
Vol 15
(2)
◽
pp. 143-155
◽
Cited By ~ 496
Author(s):
Martin Reck
◽
Rolf Kaiser
◽
Anders Mellemgaard
◽
Jean-Yves Douillard
◽
Sergey Orlov
◽
...
Keyword(s):
Lung Cancer
◽
Randomised Controlled Trial
◽
Small Cell Lung Cancer
◽
Controlled Trial
◽
Small Cell
◽
Small Cell Lung
◽
Phase 3
◽
Double Blind
◽
Previously Treated
◽
Randomised Controlled
Download Full-text
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
The Lancet
◽
10.1016/s0140-6736(16)00587-0
◽
2016
◽
Vol 387
(10030)
◽
pp. 1837-1846
◽
Cited By ~ 1206
Author(s):
Louis Fehrenbacher
◽
Alexander Spira
◽
Marcus Ballinger
◽
Marcin Kowanetz
◽
Johan Vansteenkiste
◽
...
Keyword(s):
Lung Cancer
◽
Randomised Controlled Trial
◽
Controlled Trial
◽
Small Cell
◽
Phase 2
◽
Small Cell Lung
◽
Open Label
◽
Open Label Phase
◽
Previously Treated
◽
Randomised Controlled
Download Full-text
Erratum to: The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection
Pilot and Feasibility Studies
◽
10.1186/s40814-016-0095-6
◽
2016
◽
Vol 2
(1)
◽
Cited By ~ 2
Author(s):
M. P. Snee
◽
L. McParland
◽
F. Collinson
◽
C. M. Lowe
◽
A. Striha
◽
...
Keyword(s):
Lung Cancer
◽
Randomised Controlled Trial
◽
Controlled Trial
◽
Small Cell
◽
Phase Iii
◽
Feasibility Trial
◽
Stereotactic Ablative Radiotherapy
◽
Trial Protocol
◽
Small Cell Lung
◽
Randomised Controlled
Download Full-text
The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection
Pilot and Feasibility Studies
◽
10.1186/s40814-016-0046-2
◽
2016
◽
Vol 2
(1)
◽
Cited By ~ 18
Author(s):
M. P. Snee
◽
L. McParland
◽
F. Collinson
◽
C. M. Lowe
◽
A. Striha
◽
...
Keyword(s):
Lung Cancer
◽
Randomised Controlled Trial
◽
Controlled Trial
◽
Small Cell
◽
Phase Iii
◽
Feasibility Trial
◽
Stereotactic Ablative Radiotherapy
◽
Trial Protocol
◽
Small Cell Lung
◽
Randomised Controlled
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close